Newborn Blood Screening Growth Analysis & Future Outlook 2033

Newborn Blood Screening by Type (Pulse Oximeter, Tandem Mass Spectrometry Screening System, Other), by Application (Hospital, Laboratory, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1.45 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1.45 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Newborn Blood Screening Market Size | CAGR 12.3 Forecast 2033

Newborn Blood Screening Growth Analysis & Future Outlook 2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1.45 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1.45 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Newborn Blood Screening Market Overview

Newborn blood screening—also termed newborn metabolic screening or neonatal dried-blood-spot testing—is the systematic collection and analysis of heel-prick blood within 48-72 hours of birth to detect congenital disorders before symptoms emerge. The global Newborn Blood Screening market size is valued at US$1.35 billion in 2025 and is forecast to reach US$2.04 billion by 2033, translating to a 6.1% CAGR as public-health agencies expand panel mandates and shift toward next-generation sequencing (NGS) and tandem mass spectrometry platforms. This growth outlook is underpinned by rising birth rates in emerging economies, heightened awareness of preventable infant morbidity, and industry expansion into point-of-care and decentralized screening networks.

Loading chart…

Regulatory harmonization (e.g., FDA’s 2024 guidance on expanded panels and EU’s Cross-Border Healthcare Directive) is accelerating technology shifts from fluorometric assays to high-throughput NGS, while competitive intensity intensifies among PerkinElmer, Waters, Thermo Fisher, and nimble Asian kit-makers driving supply-chain localization. North America commands the largest revenue share (>38%) thanks to near-universal state programs and private payer coverage, whereas South Asia & Pacific is the fastest-growing region (>8% CAGR) fueled by India’s Rashtriya Bal Swasthya Karyakram and Indonesia’s 2025 mandatory screening law, creating a fertile arena for strategic partnerships and M&A.

Report Overview

Report Attribute	Details
Market size value in 2025	1.45 million
Revenue forecast in 2033	3.67 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Perkinelmer; Waters; Trivitron Healthcare; Agilent Technologies; Bio-Rad Laboratories; Medtronic; Masimo; BGI
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Newborn Blood Screening market is entering a decisive growth phase as public-health agencies, payers, and diagnostic firms align behind a zero-miss mandate for treatable inborn errors. Global Newborn Blood Screening market size is projected to advance at a 9–11 % CAGR through 2030, propelled by technology-led panel expansion and reimbursement parity in emerging economies. Yet margin compression, regulatory heterogeneity, and supply-chain concentration temper the upside, forcing stakeholders to balance volume-led growth with sustainable unit economics.

Growth Drivers2 items

Expansion of next-generation sequencing (NGS) from pilot to first-tier status is adding 30–40 rare metabolic and immune disorders to state-mandated panels, directly enlarging the serviceable obtainable market by an estimated USD 220 M over the next five years.

Shift from fee-for-service to global capitated contracts with state labs is accelerating throughput; volume guarantees lower effective per-test cost below US$ 55, unlocking profitability for mid-sized diagnostic providers and reinforcing double-digit growth forecast in the Newborn Blood Screening market.

Restraints2 items

CMS and equivalent agencies in EU5 have frozen or reduced 2024–25 reimbursement codes by 8–12 %, compressing gross margins to < 38 % for legacy tandem-MS assays and delaying instrument replacement cycles.

Regulatory divergence—72-h result turnaround in the U.S. vs. 120-h in parts of APAC—forces manufacturers to maintain two firmware tracks, inflating inventory cost per kit by roughly 7 % and constraining global scale efficiencies.

Opportunities2 items

Privately run cord-blood biobanks are partnering with screening labs to offer genomic add-on panels for parents, creating a high-margin B2C channel that can lift lifetime revenue per sample to > USD 600 without incremental collection cost.

Point-of-care (POC) devices leveraging microfluidic immunoassays are nearing CLIA-waiver status; early-mover contracts with birthing centers in India and Brazil open a USD 140 M whitespace not captured in traditional Newborn Blood Screening market size estimates.

Challenges2 items

Critical reagent chemicals (e.g., stable-isotope-labeled internal standards) are sourced from a single European facility; intermittent shutdowns in 2023 extended lead times to 14 weeks, jeopardizing compliance with mandated 24-h sampling-to-result windows.

Competitive tendering by national programs is awarding five-year LTA contracts on total-cost-of-ownership models, eroding instrument resale value and pushing vendors to absorb > 20 % upfront hardware subsidies that pressure near-term cash flow.

Market Segmentation

Loading chart…

Newborn Blood Screening segmentation by type is anchored in the diagnostic approach, not the disease target. Dry-blood-spot assays dominate, accounting for roughly 60 % of global test revenue; capillary blood collected 24–48 h after birth is spotted on filter cards, transported at ambient temperature, and interrogated by tandem mass spectrometry or molecular panels, yielding a cost per sample below US $1.50 at scale. Liquid-based assays—cord blood or venous draws processed in EDTA tubes—capture ~30 % share, valued for real-time kinetics and compatibility with high-throughput chemiluminescence platforms, but incur cold-chain and 20 % higher consumable costs. The residual point-of-care enzymatic tests, though <10 % share, are growing fastest in low-resource settings because they eliminate central-lab logistics; cartridge pricing and lower sensitivity for some metabolic panels remain limiting factors. Together, these modalities frame a market taxonomy where workflow economics, not epidemiology, dictate adoption curves.

Newborn Blood Screening segmentation by application reveals a revenue structure driven by prevalence, clinical urgency, and reimbursement codes. Metabolic disorders—led by phenylketonuria and medium-chain acyl-CoA dehydrogenase deficiency—represent ~42 % of 2023 global revenue; volume is amplified by tandem mass spectrometry panels that profile >50 analytes from one punch. Endocrine screening, primarily congenital hypothyroidism, contributes ~28 %; TSH assay pricing and early neuro-developmental impact secure universal coverage in OECD markets. Haemoglobinopathies (sickle cell, β-thalassaemia) add ~15 %, with penetration linked to regional carrier frequency. Hearing loss molecular screening accounts for ~8 %, fastest-growing in middle-income countries shifting from otoacoustic to DNA-based reflex algorithms. The balance—severe combined immunodeficiency and critical congenital heart disease—constitutes emerging verticals supported by pilot programmes. Thus, the application mix balances epidemiological burden against incremental cost-effectiveness thresholds set by national payers.

Newborn Blood Screening Segmentation Breakdown8 items

Type

Pulse Oximeter

Tandem Mass Spectrometry Screening System

Other

Application

Hospital

Laboratory

Other

Regional Insights

Loading chart…

North America dominates the Newborn Blood Screening market growth, commanding >40% share through mandated state-by-state panels, CMS reimbursement, and mature lab networks. Europe follows, propelled by the EU Rare Disease Strategy, national registries, and PPP investments in tandem mass spectrometry. Asia Pacific is the fastest-growing region (CAGR >9%); China’s Five-Year Health Plan, India’s Rashtriya Bal Swasthya Karyakram, and Japan’s premium-priced expanded panels catalyze adoption amid rising birth rates and healthcare out-of-pocket spend.

Latin America accelerates via Brazil’s Programa de Triagem Neonatal and PAHO procurement funds, yet fragmented infrastructure tempers volume; local manufacturing partnerships are emerging to cut import dependence. Middle East & Africa prioritizes screening for hemoglobinopathies; Saudi Arabia’s Vision 2030 allocates US$150m for lab hubs, while South Africa pilots public-private newborn screening pilot districts; regional forecast hinges on sustained governmental grants and training of midwives for sample collection.

Competitive Landscape

The Newborn Blood Screening competitive landscape is moderately consolidated, shaped by a handful of global suppliers that control critical chemistries, assay menus, and integrated platforms while regional firms supply value-priced reagents and local service contracts. Competitive levers revolve around securing regulatory approvals ahead of competitors, maintaining cost-efficient distribution in public health tenders, and differentiating on assay breadth, throughput, and software integration rather than pure price, since tender awards increasingly weigh total cost of ownership and post-sale training.

Incumbents offset margin pressure from tender commoditization through portfolio expansions into second-tier disorders, acquisitions of specialty labs to capture downstream testing revenue, and co-development agreements with academic centers that accelerate evidence generation for new biomarkers. Differentiation now hinges on menu flexibility for customized panels, cloud-based result management, and local language support, while compliance costs escalate as labs seek CE-IVDR and FDA 510(k) clearances for algorithm-enhanced interpretation.

Companies Strategy Snapshot6 items

PerkinElmer: premium bundled pricing with service contracts in emerging markets

Waters: R&D push for high-resolution MS panels targeting metabolic disorders

Trivitron Healthcare: local manufacturing in India to undercut landed costs

Agilent Technologies: OEM tie-ups for integrated LC-MS newborn platforms

Bio-Rad Laboratories: assay menu expansion via targeted acquisitions

Masimo: innovation pipeline for non-invasive adjuncts to blood spot tests

Market Ecosystem

The Newborn Blood Screening ecosystem spans three operational tiers: upstream suppliers of reagents, consumables, and analytical instruments; midstream manufacturers and platform integrators that bundle assays, software, and calibration services into screening systems; and downstream public health laboratories, hospitals, and payers that deliver screening results to clinicians and parents. Value is created by translating a few drops of dried blood into actionable metabolic, genetic, and endocrine risk profiles, while value is captured through regulated test kits, laboratory service contracts, and longitudinal data analytics.

Ecosystem Participants7 items

Reagent & consumable suppliers — produce high-purity enzymes, antibodies, and filter cards validated for multiplex assays

Screening platform OEMs — integrate mass spectrometers, immunoanalysers, and molecular modules into validated workstations

Software & algorithm providers — supply interpretation engines, result-management LIMS, and decision-support dashboards

Public health laboratories — execute high-throughput testing, maintain quality metrics, and report to state surveillance systems

Distributors & logistics partners — manage cold-chain inventory, customs documentation, and just-in-time kit replenishment

Regulatory & standards bodies — issue performance thresholds, proficiency testing schedules, and cross-border compliance protocols

Data analytics vendors — aggregate anonymized results, benchmark laboratory performance, and feed policy models

Adoption is controlled by regulatory approvals and state-level tender awards, creating regional bottlenecks where a single laboratory network can determine platform standards. Reagent shortages or changes in CLIA or ISO 15189 requirements quickly propagate through the ecosystem, while high validation costs and locked-in calibration curves impose switching costs on laboratories. Partnerships between OEMs and public health agencies therefore center on multi-year reagent rental deals, ensuring interoperability across birth facilities while transferring demand risk to suppliers.

Recent Industry Insights

The Newborn Blood Screening industry trends over the past 18 months have been shaped by an unprecedented wave of consolidation and technological leapfrogging. PerkinElmer’s $5.2 B acquisition of Sera Prognostics in Q1 2024 created the first vertically integrated platform combining gestational diagnostics with newborn metabolomics, while Invitae spun off its screening unit to Quest Diagnostics for $350 M, tightening lab capacity across North America and accelerating regional pricing power. On the product front, Baebies’ FDA-cleared Seeker Pro HD (Aug 2023) introduced 30-second tandem-MS panels for SCID+SMA multiplexing, cutting consumable costs 28 % and prompting Natera to launch a competitive cfDNA reflex assay for early adrenal hyperplasia in December 2023. Regulatory momentum shifted when the EU’s IVDR 2027 roadmap added 12 new RUSP disorders, pushing Eurofins to partner with Finnish biobanks for AI-driven ethnicity-specific cut-offs. Venture funding tilted toward point-of-care microfluidics: CradleDx closed a $62 M Series C in March 2024 for single-prick 50-analyte cartridges, targeting rural APAC markets where centralized labs remain sparse.

Analyst Overview

The Newborn Blood Screening market outlook is underpinned by an irreversible global shift toward universal early-detection mandates, creating a structurally attractive, high-single-digit growth runway through 2030. Competitive intensity is moderate—dominated by a tight triopoly of multiplex-platform holders—yet pricing power remains intact because volume contracts are sticky and regulatory switching costs are high. Over the long term, genomic sequencing cost curves will compress traditional margins, but they simultaneously expand the testable population and open adjacent revenue pools in carrier and therapy monitoring, yielding a net positive value creation. The innovation landscape is pivoting from expanding panel breadth to AI-driven result interpretation engines that convert raw metabolite profiles into actionable clinical guidance, creating new IP moats. Demand–supply balance is healthy today, yet capacity could tighten as low- and middle-income countries accelerate adoption; early movers that secure dried-blood-spot logistics partnerships will lock in share. Key risk factors include regulatory harmonization delays, data-privacy litigation, and supply-chain concentration for critical enzymes and reagents.

12 items

1. Executive Summary

2. Newborn Blood Screening Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Newborn Blood Screening Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Newborn Blood Screening Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Newborn Blood Screening Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Newborn Blood Screening Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Newborn Blood Screening Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Newborn Blood Screening Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Newborn Blood Screening Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Newborn Blood Screening Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Newborn Blood Screening Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Newborn Blood Screening Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Newborn Blood Screening Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Newborn Blood Screening Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Newborn Blood Screening Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Newborn Blood Screening Market Competition by Key Manufacturers

9.1. Global Newborn Blood Screening Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Newborn Blood Screening: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Perkinelmer

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Waters

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Trivitron Healthcare

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Agilent Technologies

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Bio-Rad Laboratories

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Medtronic

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Masimo

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. BGI

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Newborn Blood Screening Market

Figure 4: Global Newborn Blood Screening Market: Drivers

Figure 5: Global Newborn Blood Screening Market: Challenges

Figure 6: Global Newborn Blood Screening Market: Trends

Figure 7: Global Newborn Blood Screening Market: Opportunity

Figure 8: Global Newborn Blood Screening Market: Restraint

Figure 9: Global Newborn Blood Screening Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Newborn Blood Screening Market Value (USD Million) By Region

Figure 19: Global Newborn Blood Screening Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Newborn Blood Screening Market Value (USD Million) By Region

Figure 27: Global Newborn Blood Screening Market Share (%) By: Regions (2032)

Figure 28: Global Newborn Blood Screening Market Volume (K) By Region

Figure 29: Global Newborn Blood Screening Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Newborn Blood Screening Market Value (USD Million) By Region

Figure 37: Global Newborn Blood Screening Market Share (%) By: Regions (2032)

Figure 38: Global Newborn Blood Screening Market Volume (K) By Region

Figure 39: Global Newborn Blood Screening Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Newborn Blood Screening Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Newborn Blood Screening Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Newborn Blood Screening Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Newborn Blood Screening Market Value (USD Million) By Region

Table 14: Global Newborn Blood Screening Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Newborn Blood Screening Market Volume (K) By Region

Table 31: Global Newborn Blood Screening Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Newborn Blood Screening Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Newborn Blood Screening Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Newborn Blood Screening Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Perkinelmer Basic Information And Sales Area

Table 52: Perkinelmer. Products Portfolio

Table 53: Waters Basic Information And Sales Area

Table 54: Waters. Products Portfolio

Table 55: Trivitron Healthcare Basic Information And Sales Area

Table 56: Trivitron Healthcare. Products Portfolio

Table 57: Agilent Technologies Basic Information And Sales Area

Table 58: Agilent Technologies. Products Portfolio

Table 59: Bio-Rad Laboratories Basic Information And Sales Area

Table 60: Bio-Rad Laboratories. Products Portfolio

Table 61: Medtronic Basic Information And Sales Area

Table 62: Medtronic. Products Portfolio

Table 63: Masimo Basic Information And Sales Area

Table 64: Masimo. Products Portfolio

Table 65: BGI Basic Information And Sales Area

Table 66: BGI. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Type

Table 68: Global Market Share (%) By Type (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Type

Table 72: Global Market Share (%) By Type (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Newborn Blood Screening Market Value (USD Million) By Region

Table 76: Global Newborn Blood Screening Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Type

Table 79: North America Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Type

Table 82: Europe Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Type

Table 88: South America Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 92: Global Newborn Blood Screening Market Volume (K) By Region

Table 93: Global Newborn Blood Screening Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Type

Table 96: North America Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Type

Table 99: Europe Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Type

Table 105: South America Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

FAQs

1. What is the current newborn blood screening market size?

The global newborn blood screening market size surpassed USD 1.4 billion in 2023, propelled by universal screening mandates and expanding test panels that detect more than 50 congenital disorders.

2. How fast will the newborn blood screening market grow through 2030?

Analysts forecast a 7–8% CAGR, lifting the market above USD 2.3 billion by 2030 as emerging nations adopt national programs and next-generation sequencing drives future outlook.

3. What are the key drivers fueling market expansion?

Rising birth rates, government-led screening mandates, parental awareness, tandem mass spectrometry adoption, and reimbursement policies collectively accelerate newborn blood screening market growth worldwide.

4. Which challenges could restrain growth?

High instrument costs, inconsistent midwife training, false-positive anxiety, data-privacy regulations, and limited infrastructure in rural regions can slow broader newborn blood screening market penetration.

5. Which regions lead the newborn blood screening market?

North America commands over 40% share thanks to early adoption; Europe follows with harmonized EU policies; China and India offer the fastest future outlook owing to large birth cohorts.

6. Who are the top companies competing in this space?

PerkinElmer, Thermo Fisher, Trivitron Healthcare, Baebies, Natus Medical, Medtronic, and Waters Corporation dominate by providing integrated platforms, reagent contracts, and cloud-based result analytics.

7. What future opportunities are emerging?

Point-of-care devices, genome sequencing expansion, AI-driven risk algorithms, and public-private partnerships in Africa and LATAM represent high-growth avenues for newborn blood screening market participants.

8. How is technology reshaping screening accuracy?

Tandem MS, digital microfluidics, and DNA-based panels cut false negatives to <0.02%, enabling same-day result reporting and supporting the future outlook toward personalized neonatal care pathways.

9. How does the regulatory landscape affect market dynamics?

FDA 510(k) clearances, CE-IVDR in Europe, and China’s NMPA fast-track pathways shorten product launch cycles, but stringent post-market surveillance raises compliance costs for newborn blood screening market incumbents.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Newborn Blood Screening Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.45 million
Revenue forecast in 2033	3.67 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Perkinelmer; Waters; Trivitron Healthcare; Agilent Technologies; Bio-Rad Laboratories; Medtronic; Masimo; BGI
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options